Emergent Biosolutions Inc recorded a cumulative net loss of $-177 million during 12 month ending in the second quarter 2026. The Healthcare sector has seen employees of 73 other companies achieving higher income per employee. While Emergent Biosolutions Inc 's total ranking has deteriorated compared to the previous quarter from 1532 to 2516.
Emergent BioSolutions Secures $100 Million Asset-Backed Loan Facility Amidst Strategic Financial RefocusGAITHERSBURG, Md. Oct. 02, 2024 In a significant move to bolster its financial standing and operational capabilities, Emergent BioSolutions Inc. (NYSE: EBS) announced the finalization of a new credit agreement on September 30, 2024, which established an asset-based revolving loan facility (ABL) amounting to $100 million. The agreement, inked with multiple lenders and facilitated by Wells Fargo Bank, National Association, is designed to provide Emergent with the necessary liquidity to support its ambitious multi-year transformation plan.The structure of this new credit agreement allows for revolving loan commitments with an aggregate principal amount of up to $100 million, subject to a borrowing base outlined within the terms of the agreement. Notably, the facility has a fixed maturity date set for September 30, 2029, although early maturity triggers are in place, linked to the maturation of other significant liabilities the company holds. As of September 30, 2024, Emergent reported a strong cash position of approximately $150 million, accompanied by the newly accessible $100 million under the ABL, which collectively empowers the company in navigating its financial landscape effectively.
In a decisive move aimed at bolstering its financial stability and operational trajectory, Emergent BioSolutions Inc. (NYSE: EBS), a prominent provider of critical public health products, has secured a $250 million term loan facility. This refinancing effort, orchestrated by Oak Hill Advisors (OHA) as both the Administrative Agent and sole lender, marks a pivotal moment in Emergentns journey to restore and enhance its financial profile in the face of evolving challenges within the biotech and pharmaceutical sectors. Founded in 1998, Emergent BioSolutions has positioned itself as a key player in combating public health threats, particularly through its innovative vaccines and therapeutics. However, the company faced significant financial pressure in recent years due to a range of factors, including a global pandemic that impacted demand, shifting regulatory environments, and operational hurdles that prompted a reassessment of its financial strategy.
Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
